• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconweight-loss and diet control industry

weight-loss and diet control industry

Page 6 of 10
Americans spend an average of $5,300 a year on wellness. From biohacking to walking retreats, here are the top 10 trends driving the market
Life
Americans spend an average of $5,300 a year on wellness. From biohacking to walking retreats, here are the top 10 trends driving the market
By Alexa MikhailFebruary 2, 2024
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
Retail
Novo Nordisk hits $500B market value, climbing closer to the $1T club as it forecasts Wegovy and Ozempic will juice another 29% jump in profits this year
By Ryan HoggJanuary 31, 2024
Eli Lilly and Company says its popular drugs Mounjaro and Zepbound, also known as GLP-1s, are not meant for those without obesity or type 2 diabetes.
Health
Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of for diabetes and obesity
By Alexa MikhailJanuary 4, 2024
Regulators are looking into whether weight-loss drugs like Ozempic raise the risk of suicidal thoughts
Health
Regulators are looking into whether weight-loss drugs like Ozempic raise the risk of suicidal thoughts
By Deirdre Hipwell and BloombergDecember 1, 2023
Weight loss drugs are all the rage.
Health
Pfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro
By Madison Muller and BloombergDecember 1, 2023
Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options
Newsletters
Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options
By Sheryl EstradaNovember 29, 2023
Lars Fruergaard Jorgensen holding a microphone in one hand and paper flashcards in the other hand
Health
Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs
By Prarthana PrakashNovember 27, 2023
So many Americans are using Novo Nordisk’s blockbuster weight loss-aiding Ozempic that Germany may ban exports of the drug
Retail
So many Americans are using Novo Nordisk’s blockbuster weight loss-aiding Ozempic that Germany may ban exports of the drug
By Ryan HoggNovember 16, 2023
Novo Nordisk employees who need to lose weight get an unusual perk—free Wegovy that normally costs $4,400 annually
Health
Novo Nordisk employees who need to lose weight get an unusual perk—free Wegovy that normally costs $4,400 annually
By Sanne Wass and BloombergNovember 15, 2023
a box of wegovy injectables
Retail
Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports
By Prarthana PrakashNovember 13, 2023
Weight-loss drugs are impacting everything from snack portion sizes to stomach surgery numbers as corporate America adjusts to them
Finance
Weight-loss drugs are impacting everything from snack portion sizes to stomach surgery numbers as corporate America adjusts to them
By ReutersNovember 13, 2023
Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy
Retail
Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy
By Ryan HoggNovember 9, 2023
Europe’s most valuable drugmaker Novo Nordisk is threatening the EU with a shift to the U.S.
Health
Europe’s most valuable drugmaker Novo Nordisk is threatening the EU with a shift to the U.S.
By Ryan HoggNovember 6, 2023
picture of four wegovy injections lined up
Health
Novo Nordisk isn’t alone: Sales of Ozempic rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze
By Prarthana PrakashNovember 3, 2023
Brands like Walmart and Nestle are right to worry about Wegovy. Novo Nordisk sold $900m of the weight loss drug last quarter—and 95% was in the U.S.
Health
Brands like Walmart and Nestle are right to worry about Wegovy. Novo Nordisk sold $900m of the weight loss drug last quarter—and 95% was in the U.S.
By Ryan HoggNovember 2, 2023
1...
  • 4
  • 5
  • 6
  • 7
  • 8
...10
Most Popular
Success
After donating $8 billion, Steve and Connie Ballmer create three regional philanthropies so people closest to the work can decide how the money is spentplaceholder alt text
By Sydney LakeAugust 11, 2026
Economy
U.S. Treasury is paying $3 billion a day in interest on national debt, says the CBO—having spent $10 billion to prop up the currency of its top lenderplaceholder alt text
By Eleanor PringleAugust 11, 2026
North America
Google cofounder Sergey Brin has now spent $100 million to fight California’s proposed billionaire tax—he could owe $13 billion if he losesplaceholder alt text
By Sasha RogelbergAugust 11, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.